Myqorzo MAPLE-HCM infographic comparing aficamten and metoprolol peak VO2 change in obstructive HCM

The Myqorzo MAPLE-HCM label update, announced by Cytokinetics on November 16, 2026, adds head-to-head data against the beta-blocker metoprolol to the US prescribing information for aficamten in obstructive hypertrophic cardiomyopathy (oHCM). In the 175-patient MAPLE-HCM trial, aficamten improved peak oxygen uptake by 1.1 mL/kg/min over 24 weeks while metoprolol lowered it by 1.2 mL/kg/min, a between-group difference of 2.3 mL/kg/min (P < .001). The indication itself is unchanged, but the new label gives doctors comparative evidence for using a cardiac myosin inhibitor as first-line monotherapy.

Key takeaways on Myqorzo MAPLE-HCM

  • The FDA approved a supplemental NDA adding MAPLE-HCM results to the Myqorzo (aficamten) label; the oHCM indication did not change.
  • MAPLE-HCM is the first double-blind trial to compare a cardiac myosin inhibitor directly with a beta-blocker, each given alone.
  • Aficamten beat metoprolol on exercise capacity and on five of six secondary endpoints, including symptoms, NYHA class and NT-proBNP.
  • High blood pressure was more common with aficamten (15% vs 3%), and the boxed warning for heart failure and the REMS programme remain.
  • Cytokinetics plans a separate filing for non-obstructive HCM in the fourth quarter of 2026 after the positive ACACIA-HCM trial.

Why a beta-blocker comparison matters

Beta-blockers such as metoprolol have been the usual first step for people with symptomatic oHCM for decades, even though the evidence that they improve exercise capacity is thin. Cardiac myosin inhibitors, which directly reduce the excess squeezing force of the thickened heart muscle, were first approved as add-ons or after older drugs failed to help. Aficamten itself won US approval in December 2025 on the strength of SEQUOIA-HCM, a placebo-controlled trial in patients already on background therapy.

MAPLE-HCM asked a different question: if a newly diagnosed or treatment-naive patient starts on one drug alone, which works better? Having that answer in the official label matters because it shapes guideline discussions, payer policies and what cardiologists can point to when choosing initial therapy. One of the trial’s co-authors, Dr Ahmad Masri, told HCPLive the update supports aficamten as “an acceptable option for upfront first-line monotherapy”.

MAPLE-HCM results in detail

Endpoint at 24 weeksAficamten (n = 88)Metoprolol (n = 87)Difference
Peak VO2 change (mL/kg/min)+1.1-1.22.3 (95% CI 1.5 to 3.1; P < .001)
Post-Valsalva LVOT gradientFavoured aficamten-35 mm Hg
Left atrial volume indexFavoured aficamten-7.0 mL/m2
LV ejection fractionLower with aficamten-4 percentage points
Hypertension (adverse reaction)15%3%12 points higher (by our calculation)

Patients were on average 58 years old and 58% were men. Their outflow tract gradient averaged 47 mm Hg at rest and 74 mm Hg after the Valsalva manoeuvre. Doses were titrated to 5 to 20 mg of aficamten or 50 to 200 mg of metoprolol daily, using a double-dummy design so neither patients nor doctors knew which drug was active. The benefit on peak VO2 held across prespecified subgroups, including treatment-naive patients. Left ventricular mass index was the one secondary endpoint that did not differ.

Safety: what has not changed

Myqorzo still carries a boxed warning because it lowers the heart’s pumping strength (ejection fraction) and can cause heart failure from systolic dysfunction. Echocardiograms are required before and during treatment. Starting the drug is not recommended if ejection fraction is below 55%; the dose should be reduced at 40% to under 50% and paused below 40% or if heart failure symptoms appear. Rifampin is contraindicated, and doctors are advised to recheck ejection fraction 2 to 8 weeks after starting or stopping drugs that interact through CYP2C9 and related liver enzymes. Prescribers, pharmacies and patients must enrol in the Myqorzo REMS programme in the US.

The 4-point fall in ejection fraction versus metoprolol is expected for this drug class, but it is the reason monitoring stays mandatory even as the evidence for earlier use grows.

Indian patients and access

Hypertrophic cardiomyopathy is one of the most common inherited heart diseases and is often estimated to affect about 1 in 500 people, which would mean a large number of cases in India, many undiagnosed. Aficamten is approved in the United States, China, the European Union, the United Kingdom and Canada, according to Cytokinetics. The company has not announced an Indian approval or launch, so most patients in India continue to rely on beta-blockers, calcium channel blockers, disopyramide and, where needed, septal reduction procedures. The MAPLE-HCM findings may still influence how Indian cardiologists think about the limits of beta-blocker monotherapy.

Market context

Medicines for structural heart disease sit within a broader, fast-growing cardiology drug market. Acumen Research and Consulting estimates the global congestive heart failure drugs market at USD 6.9 billion in 2022, projected to reach USD 26.1 billion by 2032 at a 14.3% compound annual growth rate, with ACE inhibitors holding the largest drug-class share in 2022. HCM is a distinct condition and is not sized separately in that report, so these figures give adjacent context rather than a direct estimate for myosin inhibitors.

What comes next

  • Non-obstructive HCM: Cytokinetics plans to file an sNDA in Q4 2026 based on ACACIA-HCM, which would open a population with no approved targeted therapy.
  • Competition: Bristol Myers Squibb’s mavacamten (Camzyos) remains the first-approved myosin inhibitor and also carries a boxed warning and REMS; comparative claims will shape prescribing.
  • Guidelines: cardiology societies may revisit whether beta-blockers should remain the default first step.

Read more FDA news in our FDA Approvals section, including the recent Klygefa approval for myasthenia gravis, and our report on baloncibart for POTS.

Frequently asked questions

What is Myqorzo used for?

Myqorzo (aficamten) is a once-daily cardiac myosin inhibitor approved in the US for adults with symptomatic obstructive hypertrophic cardiomyopathy, to improve exercise capacity and symptoms.

What did the MAPLE-HCM trial show?

In 175 patients over 24 weeks, aficamten alone improved peak oxygen uptake by 2.3 mL/kg/min more than metoprolol alone and improved five of six secondary measures, including symptoms and NYHA class.

Is aficamten better than a beta-blocker for HCM?

In MAPLE-HCM it outperformed metoprolol on exercise capacity and symptoms. It also caused more high blood pressure and lowers ejection fraction, so it requires regular heart scans. Treatment choice should be made with a cardiologist.

Is Myqorzo available in India?

Cytokinetics has not announced approval in India. The drug is approved in the US, China, the EU, the UK and Canada.

Sources: Cytokinetics press release (November 16, 2026); HCPLive report on the label update and MAPLE-HCM data. Market data: Acumen Research and Consulting, Congestive Heart Failure Drugs Market report. This article is for information only and is not medical advice. Last updated November 17, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

One thought on “Myqorzo MAPLE-HCM Label Update: Aficamten Beats Metoprolol as First-Line HCM Option”
  1. […] Metoprolol is a beta-blocker. It slows the heart and reduces the force of each beat, which lowers blood pressure and the heart’s demand for oxygen. Doctors prescribe it for high blood pressure, to prevent angina and to protect the heart after a heart attack. It is also commonly used to control heart rate in atrial fibrillation and, in some cases, in heart muscle disease; a recent label update for aficamten in hypertrophic cardiomyopathy compared that drug directly with metoprolol, as we reported in Myqorzo MAPLE-HCM Label Update. […]

Leave a Reply

Your email address will not be published. Required fields are marked *